A new collaboration between Servier Pharmaceuticals and University College London (UCL) seeks to speed the discovery of new therapies for immune-inflammatory disorders such as scleroderma. The initial two-year agreement calls ... Read more

The Scleroderma Foundation is among the recipients of nearly $200,000 in awards through the 2020 RARE Patient Impact Grant program of Global Genes, a rare disease patient advocacy organization. Twenty ... Read more

Cedars-Sinai has received a $20-million donation from Dr. and Mrs. Min H. Kao and the Kao Family Foundation to establish the Kao Autoimmunity Institute to foster research and find ... Read more

About a third of people diagnosed with scleroderma in the U.S. were prescribed immunosuppressive therapies in the first year after their diagnosis, but their symptoms were found to be ... Read more

Cantargia will start the preclinical development of a new antibody, called CAN10, intended to treat people with scleroderma and myocarditis. The company aims to launch a Phase 1 clinical ... Read more

A Phase 2a clinical trial designed to test Galapagos‘ investigational oral therapy GLPG1690 in people with diffuse cutaneous scleroderma has completed enrolling participants, the company announced. GLPG1690 is a ... Read more

Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s ... Read more

Bob Saget will host the 42nd annual “Cool Comedy — Hot Cuisine” benefit of the Scleroderma Research Foundation (SRF) on Tuesday, Dec. 10. Saget, a well-known actor and a ... Read more

A single dose of an engineered antibody known as CD45-ADC can effectively eliminate disease-causing immune cells and ease the symptoms of scleroderma in mice, studies show. CD45-ADC is an ... Read more

Health Canada has approved Ofev (nintedanib) as a treatment to slow the decline of pulmonary function in people with scleroderma-associated interstitial lung disease (SSc-ILD). The approval makes Ofev, by Boehringer Ingelheim, the first treatment ... Read more